2026-04-17T14:55:54Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/127442025-05-03T03:20:35Zcom_2072_378070com_2072_378040col_2072_378092

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research Amaral, Teresa Nanz, Lena Serna-Higuita, Lina Maria Berking, Carola ASCIERTO, PAOLO ANTONIO MUÑOZ COUSELO, EVA Anomalies cromosòmiques Melanoma - Immunoteràpia Pell - Càncer - Immunoteràpia Medicaments antineoplàstics - Ús terapèutic Avaluació de resultats (Assistència sanitària) PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antineoplastic Agents, Immunological ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Drug Therapy::Molecular Targeted Therapy DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms::Neoplasms by Histologic Type::Neoplasms::Neoplasms by Histologic Type::Nevi and Melanomas::Melanoma Other subheadings::Other subheadings::Other subheadings::/drug therapy DISEASES::Neoplasms::Neoplasms by Site::Skin Neoplasms ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Survival Analysis::Progression-Free Survival FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos::inmunoterapia antineoplásica TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::farmacoterapia::terapia molecular selectiva ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias::neoplasias por tipo histológico::neoplasias::neoplasias por tipo histológico::nevos y melanomas::melanoma Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias cutáneas TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::estadística como asunto::análisis de supervivencia::supervivencia libre de progresión Checkpoint inhibitors; Overall survival; Targeted therapy Inhibidores de puntos de control; Supervivencia global; Terapia dirigida Inhibidors de punts de control; supervivència global; Teràpia dirigida Background Over the past decade, PD-1-based immune checkpoint inhibitors (ICI) and targeted therapies (TT) with BRAF and MEK inhibitors transformed melanoma treatment. Both are widely used in the adjuvant setting. However, for patients with a BRAF V600 mutation, the optimal adjuvant therapy remains unclear due to the lack of head-to-head comparison studies. Methods We conducted a systematic review of real-world data on adjuvant therapy in stage III melanoma to determine the best option for patients with BRAF V600 mutations. Kaplan-Meier curves were generated for TT and ICI using Digitizelt software. Results Nine publications with 3625 patients were included. TT showed better relapse-free survival (RFS) at 6, 12, 24, and 36 months than ICI. A similar trend was observed for distant metastasis-free survival (DMFS), with no apparent difference in overall survival. Conclusion Real-world data suggest that adjuvant TT may be associated with better RFS and DMFS in stage III BRAF V600-mutated melanoma compared to ICI. 2025-05-03T03:20:35Z 2025-05-03T03:20:35Z 2025-05-03T03:20:35Z 2025-03-11T11:16:39Z 2025-03-11T11:16:39Z 2024 2025-01 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/12744 European Journal of Cancer;215 https://doi.org/10.1016/j.ejca.2024.115160 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Elsevier Scientia